OneSource Specialty Pharma (NSE:ONESOURCE) NonCurrent Deferred Revenue: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ONESOURCE OneSource Specialty Pharma Ltd NSE:ONESOURCE
8 GF Score
Price ₹1,483.60
! 3 Warning Signs
View Full Analysis

What is OneSource Specialty Pharma NonCurrent Deferred Revenue?

OneSource Specialty Pharma NSE:ONESOURCE -2.14% 8 NonCurrent Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

OneSource Specialty Pharma's non-current deferred revenue for the quarter that ended in Jun. 2026 was ₹0 Mil.

OneSource Specialty Pharma NonCurrent Deferred Revenue Related Terms

OneSource Specialty Pharma NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for OneSource Specialty Pharma's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OneSource Specialty Pharma NonCurrent Deferred Revenue Chart

OneSource Specialty Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Revenue
0.00 0.00 25.62 0.00

OneSource Specialty Pharma Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ONESOURCE
8GF Score
OneSource Specialty Pharma Ltd NSE:ONESOURCE
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of ₹0 Mil mean?
OneSource Specialty Pharma (NSE:ONESOURCE) has a NonCurrent Deferred Revenue of ₹0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on OneSource Specialty Pharma and its competitors.
Is OneSource Specialty Pharma's NonCurrent Deferred Revenue too high?
OneSource Specialty Pharma's current NonCurrent Deferred Revenue is ₹0 Mil. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's NonCurrent Deferred Revenue compare to VRTX and REGN?
OneSource Specialty Pharma's NonCurrent Deferred Revenue of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on OneSource Specialty Pharma and its competitors. OneSource Specialty Pharma's current NonCurrent Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current NonCurrent Deferred Revenue of ₹0 Mil. The current NonCurrent Deferred Revenue is ₹0 Mil. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current NonCurrent Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OneSource Specialty Pharma Business Description

Other Exchanges 544292:India
Address Bannerghatta Road, Star 1, Opp IIM Bangalore, Bilekahalli, Bangalore, KA, IND, 560076
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score

Get the complete analysis for NSE:ONESOURCE

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,483.60
Price